Keywords:
liver cirrhosis, hepatitis B, D and C viruses, subcompensation, IL-4, IL-6.References
Ardolino E., Wang S. S., Patwardhan V. R. Evidence of significant ceftriaxone and quinolone resistance in cirrhotics with spontaneous bacterial peritonitis //Digestive Diseases and Sciences. – 2019. – Т. 64. – №. 8. – С. 2359-2367.
Atta S. et al. Ascitic Fluid Cytokines in Chronic Liver Disease: A Possible Prognostic Tool //Digestive Diseases. – 2021. – Т. 39. – №. 5. – С. 534-539.
Bashyam M, Lepore M, Harbord ManagementJ Hosp Med (Lond). 2015 Feb;76(2) :P.28-32.
Desai AP, Mohan P, Nokes B, et al. Increasing economic burden in hospitalized patients with cirrhosis: analysis of a national database. Clin Transl Gastroenterol 2019;10:Р.62.
5.O'Beirne J., Foxton M., Heneghan M. Management of cirrhosis and ascites. N Engl J Med. 2004 Jul 15;351(3)-P.300-1.
P.Ginеs, А.Cаrdenas, V.Arroyo, J. Rodеs. Management of cirrhosis and ascites. N Engl J Med. 2004 Apr 15;350(16)Р.1646-54.
Schwabl P. et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites //Liver international. – 2015. – Т. 35. – №. 9. – С. 2121-2128.
Wong F, Bernardi M, Balk R, et al; International Ascites Club. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005;54: Р.718-725.
9.World Health Organization. Global hepatitis report. Geneva, Switzerland; 2017. (Electronic resource). URL: http://www.who.int/hepatitis/publications/global-hepatitis- eport2017/ en/ (access date: 11.09.2019).